Pulmonx Corporation (LUNG) Reports Q2 Loss, Beats Revenue Estimates

Pulmonx Corporation (LUNG) reported a Q2 loss of $0.38 per share, outperforming the Zacks consensus estimate of a $0.40 loss by 5.00%, and achieved revenues of $23.86 million, surpassing estimates by 1.25% and up from $20.78 million year-ago. Despite these beats and a consistent track record of exceeding consensus EPS and revenue estimates over the past four quarters, the stock has significantly underperformed, declining 54.5% year-to-date against the S&P 500's 8.3% gain. The sustainability of any immediate price movement will largely hinge on management's commentary during the earnings call, with the stock currently holding a Zacks Rank #3 (Hold), indicating expected in-line performance.

Analysis

Pulmonx Corporation (LUNG) reported a smaller-than-expected quarterly loss and a revenue beat for the quarter ended June 2025, demonstrating operational outperformance. The company posted a loss of $0.38 per share, a 5.00% positive surprise against the consensus estimate of a $0.40 loss, and a slight improvement from the $0.39 loss a year ago. Revenues grew a significant 14.8% year-over-year to $23.86 million, also surpassing estimates by 1.25%. This quarter continues a trend of positive execution, with the company beating EPS estimates for four consecutive quarters and revenue estimates in three of the last four. However, this operational consistency is starkly at odds with its market performance; the stock has declined 54.5% year-to-date while the S&P 500 gained 8.3%. The forward-looking picture remains uncertain, with a neutral Zacks Rank #3 (Hold) suggesting in-line market performance and mixed pre-earnings estimate revisions. Future stock trajectory will be highly dependent on management's guidance from the earnings call, though the company benefits from being in the Medical Info Systems industry, which ranks in the top 23% of over 250 Zacks industries.

Key Decisions for Investors

• Investors should closely scrutinize management's commentary on the upcoming earnings call to understand the significant disconnect between consistent operational beats and the stock's severe 54.5% year-to-date underperformance.
• Given the neutral Zacks Rank #3 (Hold) and mixed analyst sentiment preceding the report, a wait-and-see approach may be prudent until post-earning estimate revisions provide a clearer directional catalyst for the stock.
• Evaluate the company's path to profitability, as the market's deeply negative sentiment suggests that the 14.8% year-over-year revenue growth is being overshadowed by concerns about ongoing losses.